Xue Du

Xue Du

Auto-generated profile, based on publicly available information

Xue Du

Key laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Center for Molecular Diagnosis, Peking University Cancer Hospital & Institute, Beijing, China

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 February 2018 in Thoracic Cancer
Verified
Journal Article
Open access
PDF file
XDXue Du
Xue Du
YSYun Shao
Yun Shao
HQHai‐Feng Qin
Hai‐Feng Qin
YTyanhong tai
yanhong tai
HGHongjun Gao
Hongjun Gao
The ALK gene encodes a transmembrane tyrosine kinase receptor. ALK is physiologically expressed in the nervous system during embryogenesis, but its expression decreases postnatally. ALK first emerged in the field of oncology in 1994 when it was identified to fuse to NPM1 in anaplastic large‐cell lymphoma. Since then, ALK has been associated with other types of cancers, including non‐small‐cell lung cancer (NSCLC). More than 19 different ALK fusion partners have been discovered in NSCLC, including EML4, KIF5B, KLC1, and TPR. Most of these ALK fusions in NSCLC patients respond well to the ALK inhibitor, crizotinib. In this paper, we reviewed fusion partner genes with ALK, detection methods for ALK‐rearrangement (ALK‐R), and the ALK‐tyrosine kinase inhibitor, crizotinib, used in NSCLC patients.

6 September 2021 in Thoracic Cancer
Verified
Journal Article
Open access
PDF file
XDXue Du
Xue Du
JZJun Zhang
Jun Zhang
HGHongjun Gao
Hongjun Gao
YTyanhong tai
yanhong tai
Background detection of anaplastic lymphoma receptor tyrosine kinase gene (ALK) rearrangements in patients with non-small-cell lung cancer (NSCLC) has become a routine pathological diagnosis worldwide. Methods there are three major conventional diagnostic methods for ALK fusions: fluorescent in situ hybridization (FISH); immunohistochemistry (Ventana IHC (D5F3)); and polymerase chain reaction (PCR). Next-generation sequencing (NGS) technology as is a new tool for ALK status detection with great potential. These four methods are highly consistent in detecting ALK status (coincidence rate >96%). However, discrepancies in ALK status have been found in some patients among these methods, which causes confusion for clinicians. Results and conclusion in this study, we analyzed two patients whose ALK statuses were not consistent using these four methods. We explored the potential reasons for deviation of the test results and found a novel EML4-ALK break site, which had been not described previously.

28 February 2022 in npj Breast Cancer
Verified
Journal Article
Open access
PDF file
XDXue Du
Xue Du
ZZZhe Zhou
Zhe Zhou
YSYun Shao
Yun Shao
KQKun Qian
Kun Qian
YWYongfang Wu
Yongfang Wu
YTyanhong tai
yanhong tai
Currently, tumor-infiltrating lymphocytes (TILs) in invasive breast cancers are assessed solely on the basis of their number, whereas their spatial distribution is rarely investigated. Therefore, we evaluated TILs in 579 patients with invasive breast cancer of no special type (IBC-NST) with a focus on their spatial distributions in tumor center (TC) and invasive margin (IM). We also assessed a new factor, namely para-tumor infiltrating lymphocytes (PILs) in the para-tumor lobular area (Para). Five immunoarchitectural patterns (IPs) were observed, which were significantly associated with clinicopathological features, especially molecular subtypes, histological grades, clinical stages, and programmed death-ligand 1 (PD-L1) expression. High-TIL density (IP1/2) correlated with favorable disease-free survival (DFS) in TNBC patients (p = 0.04), but opposite results were observed for luminal B subtype patients (both the lowest TIL and PIL densities (IP5) correlated with good DFS, p = 0.013). Luminal B patients with high TILs in the IM and low TILs in the TC (IP3) exhibited the worst DFS, whereas those with low TILs (similar to IP5) and high PILs (IP4) exhibited poor DFS. We also identified TIL subpopulations with significantly different IPs. Our findings suggest that IP can be a potential prognostic factor for tumor immunity in IBC.

14 October 2024 in JMIR Preprints
Verified
Preprint
Open access
SZSheng Zheng
Sheng Zheng
YFYi Feng
Yi Feng
JLJieran Long
Jieran Long
XLXiang Li
Xiang Li
MZMeng Zhang
Meng Zhang
XLXudong Lu
Xudong Lu
BACKGROUND The rapid advancement of next-generation sequencing has significantly expanded the landscape of precision medicine. However, health care professionals face increasing challenges in keeping pace with the growing body of oncological knowledge and integrating it effectively into clinical workflows. Precision oncology decision support (PODS) tools aim to assist clinicians in navigating this complexity, yet their current functionalities only partially address clinical needs. A lack of comprehensive needs assessment may result in unaddressed requirements, limiting the effectiveness of these tools in real-world practice. OBJECTIVE This study aimed to explore clinicians’ needs and expectations regarding the functionalities of integrated PODS tools, providing insights into essential features that could enhance their usability and impact. METHODS We conducted a qualitative investigation at Peking University Cancer Hospital to explore clinicians’ needs and expectations for the functions of integrated PODS tools. Data were collected through 143 structured participant observations during multidisciplinary team meetings and 17 in-depth semistructured interviews with a diverse group of oncology specialists, including physicians, surgeons, molecular biologists, radiotherapists, radiologists, and pathologists. Thematic analysis was applied to identify key functional requirements, and a requirements framework was formed. RESULTS Three overarching functional needs emerged: (1) better access to oncological knowledge, including support for therapy selection (guidelines, conferences, and consensuses), clinical trials, drug and treatment information, and complex case knowledge, as well as improved diagnostic and prognostic insights; (2) clinical contextualization and resource navigation, referring to the process of contextualizing scientific knowledge within real-world clinical settings, including access to clinical trials and drugs, along with predictive models for treatment response; and (3) support abilities in the decision-making process, highlighting the need for integration of flexible biological knowledge and phenotypic data; automated patient information synthesis; improved data visualization; and optimized retrieval, recommendation, and question-answering functionalities. A functional framework for integrated PODS tools was proposed based on these findings. CONCLUSIONS The study conducted a qualitative descriptive observation and interview in the use, needs of integrated PODS tools. PODS tools serve as complex, multilevel decision support systems. A clear understanding of clinicians’ actual needs is crucial for their refinement and practical adoption. By capturing perspectives directly from oncology professionals, this study provides actionable insights into the functional enhancements required for PODS tools, ultimately aiming to bridge the gap between genomic advancements and clinical decision-making in precision oncology. CLINICALTRIAL

8 September 2025 in JMIR Human Factors
Verified
Journal Article
Open access
SZSheng Zheng
Sheng Zheng
YFYi Feng
Yi Feng
JLJieran Long
Jieran Long
XLXiang Li
Xiang Li
MZMeng Zhang
Meng Zhang
XLXudong Lu
Xudong Lu
Background: The rapid advancement of next-generation sequencing has significantly expanded the landscape of precision medicine. However, health care professionals face increasing challenges in keeping pace with the growing body of oncological knowledge and integrating it effectively into clinical workflows. Precision oncology decision support (PODS) tools aim to assist clinicians in navigating this complexity, yet their current functionalities only partially address clinical needs. A lack of comprehensive needs assessment may result in unaddressed requirements, limiting the effectiveness of these tools in real-world practice. Objective: This study aimed to explore clinicians’ needs and expectations regarding the functionalities of integrated PODS tools, providing insights into essential features that could enhance their usability and impact. Methods: We conducted a qualitative investigation at Peking University Cancer Hospital to explore clinicians’ needs and expectations for the functions of integrated PODS tools. Data were collected through 143 structured participant observations during multidisciplinary team meetings and 17 in-depth semistructured interviews with a diverse group of oncology specialists, including physicians, surgeons, molecular biologists, radiotherapists, radiologists, and pathologists. Thematic analysis was applied to identify key functional requirements, and a requirements framework was formed. Results: Three overarching functional needs emerged: (1) better access to oncological knowledge, including support for therapy selection (guidelines, conferences, and consensuses), clinical trials, drug and treatment information, and complex case knowledge, as well as improved diagnostic and prognostic insights; (2) clinical contextualization and resource navigation, referring to the process of contextualizing scientific knowledge within real-world clinical settings, including access to clinical trials and drugs, along with predictive models for treatment response; and (3) support abilities in the decision-making process, highlighting the need for integration of flexible biological knowledge and phenotypic data; automated patient information synthesis; improved data visualization; and optimized retrieval, recommendation, and question-answering functionalities. A functional framework for integrated PODS tools was proposed based on these findings. Conclusions: The study conducted a qualitative descriptive observation and interview in the use, needs of integrated PODS tools. PODS tools serve as complex, multilevel decision support systems. A clear understanding of clinicians’ actual needs is crucial for their refinement and practical adoption. By capturing perspectives directly from oncology professionals, this study provides actionable insights into the functional enhancements required for PODS tools, ultimately aiming to bridge the gap between genomic advancements and clinical decision-making in precision oncology.

18 May 2023 in Frontiers in Neuroscience
Verified
Journal Article
Open access
Chun LiChun Li
Chun Li
JMJihong Meng
Jihong Meng
BXBaoxin Xu
Baoxin Xu
XLXiaodong Li
Xiaodong Li
MLMiaomiao Li
Miaomiao Li
WMWeining Ma
Weining Ma
Objective: This study aimed to evaluate whether CT angiography (CTA) manifestations in anterior cerebral artery a1 segment (A1) were related to the hemodynamics in patients with internal carotid artery stenosis (ICAS).Methods: A total of 97 cases were selected. The degree of ICAS and symmetry of A1 were evaluated by CTA examination. Hemodynamic indexes were detected by transcranial Doppler (TCD). The differences in CTA presentations of A1 and hemodynamics between the vessels on the stenotic and contralateral sides were analyzed according to the different degrees of stenosis. The degree of ICAS according to the different manifestations of A1 and the hemodynamics of A1’s adjacent vessels were also analyzed.Results: In the case of unilateral ICAS, the difference in Vm of A1 between the stenotic and the contralateral side was the most significant relative to the stenosis degree. When unilateral ICAS was ≥70%, the presentation of A1 on the stenotic side was more slender or non-visualized compared to that on the contralateral side, while in cases with unilateral stenosis <70% or bilateral stenosis with a similar degree of stenosis, A1 were mainly symmetrical. When A1 on the side of ICAS was slender or non-visualized, the Vm of A1 was significantly slower than that on the contralateral side (P < 0.001).Conclusion: The CTA manifestations of A1 on the side of ICAS embodied the overall changes of the intracranial hemodynamics after ICAS. A combination of TCD and CTA examination of A1 can assist in judging the location and degree of ICAS.